Thr916
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr916  -  LRRC16 (human)

Site Information
DLDTCMMtPKSKRKS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 453665

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 )
Disease tissue studied:
breast cancer ( 4 , 8 ) , breast ductal carcinoma ( 4 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 , 4 ) , lung cancer ( 8 , 9 , 11 ) , non-small cell lung cancer ( 8 , 9 , 11 ) , non-small cell lung adenocarcinoma ( 9 ) , ovarian cancer ( 4 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:
'stem, embryonic' ( 12 ) , breast ( 1 , 4 ) , BT-20 (breast cell) ( 8 ) , H2009 (pulmonary) ( 8 ) , H2077 (pulmonary) ( 8 ) , H2887 (pulmonary) ( 8 ) , H322 (pulmonary) ( 8 ) , H322M (pulmonary) ( 8 ) , HCC1937 (breast cell) ( 8 ) , HCC78 (pulmonary) ( 9 ) , HeLa (cervical) ( 3 , 7 , 10 , 15 , 16 ) , HOP62 (pulmonary) ( 8 ) , liver ( 5 ) , MCF-7 (breast cell) ( 8 ) , MDA-MB-468 (breast cell) ( 8 ) , NCI-H1395 (pulmonary) ( 8 ) , NCI-H1650 (pulmonary) ( 11 ) , NCI-H2030 (pulmonary) ( 8 ) , NCI-H3255 (pulmonary) ( 13 , 14 ) , ovary ( 4 ) , WM239A (epidermal) ( 2 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

3

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

4

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

5

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

6

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

7

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

8

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

9

Possemato A (2011) CST Curation Set: 11921; Year: 2011; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Hegemann B, et al. (2011) Systematic phosphorylation analysis of human mitotic protein complexes. Sci Signal 4, rs12
22067460   Curated Info

11

Possemato A (2010) CST Curation Set: 9732; Year: 2010; Biosample/Treatment: cell line, H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

12

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

13

Possemato A (2009) CST Curation Set: 7323; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

14

Possemato A (2009) CST Curation Set: 7322; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

15

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

16

Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5
15302935   Curated Info